ArticleBMJ oncology2024
Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials.
Brody Dennis et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it